Retatrutide Half-Life: What the Research Shows (2026)

What “half-life” means in this context

Half-life is the time it takes for a compound’s concentration in the bloodstream to fall by half. It’s a pharmacokinetic property, not a claim about how a compound performs — it just describes how long the molecule persists in circulation once introduced into a biological system. For researchers designing a study protocol, half-life determines sampling windows, washout periods between study phases, and how frequently a compound needs to be reintroduced to maintain steady-state concentration in a model.

Reported half-life range

Published pharmacokinetic data from retatrutide’s Phase 2 trial program (Jastreboff et al., New England Journal of Medicine, 2023) reported a terminal elimination half-life in the range of approximately 5–6 days in human subjects, consistent with its design as a long-acting triple agonist. That half-life is the pharmacological basis for the once-weekly interval used across the trial’s dosing protocol — it’s long enough that weekly reintroduction maintains relatively stable plasma concentration without the sharp peak-and-trough pattern seen with shorter-acting compounds.

For comparison, tirzepatide’s reported terminal half-life is roughly 5 days, and semaglutide’s is close to 7 days — all three land in a similar multi-day range, which is part of why all three were engineered around a weekly interval rather than a daily one. See our full comparison of the three triple/dual/mono-agonist compounds for how the structural differences behind that shared half-life range play out mechanistically.

Why half-life matters for research design

In a lab setting, half-life data is what determines several practical protocol decisions:

Sampling schedule: researchers tracking plasma concentration over time need sampling intervals short enough to capture the elimination curve accurately, not just endpoints.

Washout periods: if a study design calls for a compound to fully clear before a subsequent phase begins, five half-lives is the standard rule-of-thumb threshold researchers use to treat a compound as functionally eliminated — for retatrutide’s reported range, that puts full clearance in the neighborhood of several weeks, not days.

Storage and handling implications: a molecule this stable in circulation also tends to be relatively stable in solution when reconstituted and refrigerated, which is part of why our storage and handling guide recommends the refrigeration windows it does — though solution stability and biological half-life are separate properties measured differently, so treat that guide as the source for handling specifics rather than extrapolating from the half-life figures here.

What this data doesn’t tell you

Half-life describes pharmacokinetics in the trial population it was measured in — it is not a personalized protocol, and it does not translate into a specific dosing schedule for any individual use case. Retatrutide remains a research-use-only compound, not an FDA-approved therapeutic, and none of the figures above are a substitute for a study’s own protocol design. If you’re trying to understand the receptor mechanism this half-life data is describing, our dosage and mechanism guide covers the GLP-1/GIP/glucagon triple-agonist pathway in more depth.

Related guides

• Where to Buy Retatrutide: Complete Buyer’s Guide
• Retatrutide Dosage & Mechanism Guide
• Retatrutide vs. Tirzepatide vs. Semaglutide
• Storage & Handling Guide
• Retatrutide FAQ

For laboratory and in vitro research use only. Not for human or veterinary use. Not an FDA-approved product.